Dr Alison Stopeck - University of Arizona Cancer Center
Among patients with bone metastasis from breast cancer, denosumab was superior to zoledronic acid in reducing the incidence of complications from bone metastases. Denosumab prevented more events, was better tolerated and is more convenient for patients. Official San Antonio Breast Cancer Symposium press conference.